AVEO Pharmaceuticals
AVEO
AVEO was delisted on the 19th of January, 2023.
90 hedge funds and large institutions have $173M invested in AVEO Pharmaceuticals in 2018 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 24 increasing their positions, 23 reducing their positions, and 12 closing their positions.
628% more call options, than puts
Call options by funds: $10.5M | Put options by funds: $1.44M
67% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 12
7% more funds holding
Funds holding: 84 → 90 (+6)
4% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 23
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1.52% less ownership
Funds ownership: 51.82% → 50.31% (-1.5%)
20% less capital inflows, than outflows
Capital inflows: $14.6M | Capital outflows: $18.2M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$4.18M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.87M |
| 3 |
Goldman Sachs
New York
|
+$1.58M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.29M |
| 5 |
Tibra Equities Europe
London,
United Kingdom
|
+$756K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Sphera Funds Management
Tel Aviv,
Israel
|
-$3.63M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$2.47M |
| 3 |
Avoro Capital Advisors
New York
|
-$2.27M |
| 4 |
Emory University
Atlanta,
Georgia
|
-$1.68M |
| 5 |
Armistice Capital
New York
|
-$1.67M |
AVEO Hedge Fund Activity: Q1 2018 in Review
90 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in AVEO Pharmaceuticals (AVEO) for Q1 2018, worth a combined $173M — up 1.3% from $171M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new AVEO positions and 12 closed out — a net gain of 8 holders — while 24 added to existing stakes and 23 trimmed.
The largest buyer was Millennium Management, adding an estimated $4.18M. The largest seller was Sphera Funds Management, exiting entirely with an estimated $3.63M sold.
- 90 institutional investors held AVEO Pharmaceuticals (AVEO) as of Q1 2018, up from 84 in Q4 2017.
- Funds reported $173M of AVEO Pharmaceuticals stock for Q1 2018, up 1.3% quarter-over-quarter.
- 20 funds opened new AVEO Pharmaceuticals positions in Q1 2018 and 12 closed out, a net change of +8 holders.
- The largest AVEO Pharmaceuticals buyer in Q1 2018 was Millennium Management, an estimated $4.18M added.
- The largest AVEO Pharmaceuticals seller in Q1 2018 was Sphera Funds Management, an estimated $3.63M sold.
Based on aggregated 13F filings for Q1 2018.